Data shows US advertising spend increasing for pharma manufacturers

Even with increased availability, access to GLP-1 therapies can be challenging for employers and healthcare consumers due to affordability. Rae McMahan, SVP of Payer Solutions at Prescryptive, talked with Reuters about the historic surge in GLP-1 advertising spend and why treatment decisions must always ultimately depend on informed conversations between patients and their physicians, particularly as access, pricing, and coverage remain challenging.

The impact of GLP-1s on the prescription drug ecosystem is well known. Employers are seeking alternatives to traditional GLP-1 coverage models at the same time that pharmaceutical manufacturers are innovating direct-to-patient models that require clear clinical guardrails. Prescryptive’s platform enables these clinically governed, employer-focused programs to scale through Centers of Excellence.

Increased advertising of these groundbreaking drugs also signals a new era where direct access is the new standard in healthcare. For pharma manufacturers leading this charge, Prescryptive powers transparent pricing without structural interference in our Marketplace, and a platform that powers Direct-to-Patient pathways that help get patients on therapy directly, at an affordable cost.

See the full article in Reuters and reach out about our solutions that are rewriting the script.